Eradication of primary murine fibrosarcomas and induction of systemic immunity by adenovirus mediated interferon β gene therapy

Cancer Research

Volumn 59, Issue 20, 1999, Pages 5202-5208

  Lu, Weixin ^a   Fidler, Isaiah J ^a   Dong, Zhongyun ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CYCLINE; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; FIBROSARCOMA; GENE THERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR IMMUNITY;

ADENOVIRIDAE; ANIMALS; FEMALE; FIBROSARCOMA; GENE THERAPY; IMMUNOHISTOCHEMISTRY; INTERFERON-BETA; MICE; MICE, INBRED C3H; MICE, NUDE; PROLIFERATING CELL NUCLEAR ANTIGEN; T-LYMPHOCYTES;

EID: 0032719471     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Lokshin, A., Mayotte, J. E., and Levin, M. L. Mechanism of Interferon β-induced squamous differentiation and programmed cell death in human non-small-cell lung cancer cell lines. J. Natl. Cancer Inst., 87: 206-212, 1995.
2. Belhumeur, P., Lanoix, J., Blais, Y., Forget, D., Steyaert, A., and Skup, D. Action of spontaneously produced β interferon in differentiation of embryonal carcinoma cells through an auloinduction mechanism. Mol. Cell. Biol., 13: 2846-2857, 1993.
3. Qin, X. Q., Runkel, L., Deck, C., DeDios, C., and Barsoum, J. Interferon-β induces S phase accumulation selectively in human transformed cells. J. Interferon Cytokine Res., 17: 355-367, 1997.
4. Fujihara, M., Ito, N., Pace, J. L., Watanabe, Y., Russell, S. W., and Suzuki, T. Role of endogenous interferon-β in lipopolysaccharide-triggered activation of the inducible nitric oxide synthase gene in a mouse macrophage cell line, J774. J. Biol. Chem., 269: 12773-12778, 1994.
5. Riches, D. W., and Underwood, G. A. Expression of interferon-β during the triggering phase of macrophage cytocidal activation: evidence for an autocrine/paracrine role in the regulation of this state. J. Biol. Chem., 266: 24785-24792, 1991.
6. Fujimiya, Y., Wagner, R. J., Groveman, S., Sielaff, K., Kohsaka, T., and Nakayama, M. In vivo priming effects of interferon-β ser on NK activity of peripheral blood mononuclear cells in cancer patients. Ther. Immunol., 2: 15-22, 1995.
7. Senik, A., Gresser, I., Maury, C., Gidlund, M., Orn, A., and Wigzell, H. Enhancement by interferon of natural killer cell activity in mice. Cell Immunol., 44: 186-200, 1979.
8. Brem, H., Gresser, I., Grosfeld, J., and Folkman, J. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J. Pediatr. Surg., 28: 1253-1257, 1993.
9. Stout, A. J., Gresser, I., and Thompson, W. D. Inhibition of wound healing in mice by local interferon α/β injection. Int. J. Exp. Pathol., 74: 79-85, 1993.
10. Singh, R. K., Gutman, M., Bucana, C. D., Sanchez, R., Llansa, N., and Fidler, I. J. Interferons α and β downregulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci. USA, 92: 4562-4566, 1995.
11. Kaido, T., Gresser, I., Maury, C., Maunoury, M. T., Vignaux, F., and Belardelli, F. Sensitized T lymphocytes render DBA/2 beige mice responsive to IFN αlβ therapy of Friend erythroleukemia visceral metastases. Int. J. Cancer, 54: 475-481, 1993.
12. Kaido, T. J. Intranasal administration of IFN-α/β inhibits the development of visceral tumor metastases. J. Interferon Cytokine Res., 17: 31-36, 1997.
13. Sarkar, S., Flores, I., De Rosa, C., Ozzello, L., Ron, Y., and Pestak, S. Injection of irradiated B16 melanoma genetically modified to secrete IFN-α causes regression of an established tumor. Int. J. Oncol., 7: 17-24, 1995.
14. Garaci, E., Pica, F., Mastino, A., Palamara, A. T., Belardelli, F., and Favalli, C. Antitumor effect of thymosin α1/interleukin-2 or thymosin α1/interferon α,β following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells. J. Immunother., 13: 7-17, 1993.
15. Bulbul, M. A., Huben, R. P., and Murphy, G. P. Interferon-β treatment of metastatic prostate cancer. J. Surg. Oncol., 33: 231-233, 1986.
16. Einhorn, S., and Grander, D. Why do so many cancer patients fail to respond to intetferon therapy? J. Interferon Cytokine Res., 16: 275-281, 1996.
17. Schiller, J. H., Storer, B., Bittner, G., Willson, J. K., and Borden, E. C. Phase II trial of a combination of interferon-β ser and interferon-γ in patients with advanced malignant melanoma. J. Interferon Res., 8: 581-589, 1988.
18. Salmon, P., Le Cotonnec, J. Y., Galazka, A., Abdul-Ahad, A., and Darragh, A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers. J. Interferon Cytokine Res., 16: 759-764, 1996.
19. Dong, Z., Juang, S. H., Kumar, R., Eue, I., Xie, K., Bielenberg, D., Lu, W., Bucana, C., Yang, X., and Fidler, I. J. Suppression of tumorigenicity and metastasis in murine UV-2237 fibrosarcoma cells by infection with a retroviral vector harboring the interferon-β gene. Cancer Immunol. Immunother., 46: 137-146, 1998.
20. Xie, K., Bielenberg, D., Huang, S., Xu, L., Salas, T., Juang, S., Dong, Z., and Fidler, I. J. Abrogation of tumorigenicity and metastasis of murine and human tumor cells by transfection with murine IFN-β gene: possible role of nitric oxide. Clin. Cancer Res., 3: 2283-2294, 1997.
21. Dong, Z., Greene, G., Pettaway, C., Dinney, C. P. N., Eue, I., Lu, W., Bucana, C. D., Balbay, M. D., Bielenberg, D., and Fidler, I. J. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-β. Cancer Res., 59: 872-879, 1999.
22. Raz, A., Hanna, N., and Fidler, I. J. In vivo isolation of a metastatic tumor cell variant involving selective and nonadaptive processes. J. Natl. Cancer Inst., 66: 183-189, 1981.
23. Kripke, M. L. Speculations on the role of ultraviolet radiation in the development of malignant melanoma. J. Natl. Cancer Inst., 63: 541-548, 1979.
24. Kripke, M. L. Latency, histology, and antigenicity of tumors induced by ultraviolet light in three inbred mouse strains. Cancer Res., 37: 1395-1400, 1977.
25. Talmadge, J. E., and Fidler, I. J. Enhanced metastatic potential of tumor cells harvested from spontaneous metastases of heterogeneous murine tumors. J. Natl. Cancer Inst., 69: 975-980, 1982.
26. Nielsen, L. L., Gumani, M., Syed, J., Dell, J., Hartman, B., Cartwright, M., and Johnson, R. C. Recombinant El-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models. Hum. Gene Ther., 9: 681-694, 1998.
27. Parks, R. J., Chen, L., Anton, M., Sankar, U., Rudnicki, M. A., and Graham, F. L. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA, 93: 13565-13570, 1996.
28. Gavrieli, Y., Shermen, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell. Biol. 119: 493-501, 1992.
29. Wilson, G. D., Camplejohn, R. S., Martindale, C. A., Brock, A., Lane, D. P., and Barnes, D. M. Flow cytometric characterisation of proliferating cell nuclear antigen using the monoclonal antibody PC10. Eur. J. Cancer, 12: 2010-2017, 1992.
30. Fleischmann, C. M., Stanton, G. J., and Fleischmann, W. R., Jr. Enhanced in vivo sensitivity to interferon with in vitro resistant B16 tumor cells in mice. Cancer Immunol. Immunother., 39: 148-154, 1994.
31. Qin, X. Q., Tao, N., Dergay, A., Moy, P., Fawell, S., Davis, A., Wilson, J. M., and Barsoum, J. Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc. Natl. Acad. Sci. USA, 95: 14411-14416, 1998.
32. Sreevalsan, T. Biologic therapy with interferon-α and -β: preclinical studies. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Biologic Therapy of Cancer: Principles and Practice, Ed. 2, pp. 347-364. Philadelphia: J. B. Lippincott, 1995.
33. Dong, Z., Yang, X., and Fidler, I. J. Neutralization of endogenous interferon-β increases the efficiency of adenoviral vector-mediated gene transduction. J. Interferon Cytokine Res., 17: 401-407, 1997.
34. Resta, L., Troia, M., Russo, S., Colucci, G. A., Sabatini, R., Loiudice, L., and Cagnazzo, G. Variations of lymphocyte subpopulations in vulvar condylomata during therapy with β-interferon. Clin. Exp. Obstet. Gynecol., 19: 120-124, 1992.
35. Nakayama, J., Takeuchi, M., Mayumi, H., Nagae, S., Matsuda, K., Yasui, H., Takahashi, S., and Hori, Y. Hyperthermic isolated limb perfusion with intra-arterial administration of carboplatin and/or interferon-β for the treatment of malignant melanoma of the leg. J. Dermatol., 21: 915-922, 1994.
36. Vieillard, V., Lauret, E., Rousseau, V., and De Maeyer, E. Blocking of retroviral infection at a step prior to reverse transcription in cells transformed to constitutively express inlerferon β. Proc. Natl. Acad. Sci. USA, 91: 2689-2693, 1994.
37. Onji, M., Yamaguchi, S., Masumoto, T., Akbar, S. M., Kajino, K., and Ohta, Y. Induction of the interleukin-2 receptor (p55) by interferons. J Interferon Res., 11: 237-241, 1991.
38. Barni, S., Lissoni, P., Ardizzola, A., Vigore, L., Vezzo, R., Rescaldani, R., and Tancini, G. Immunotherapy with low-dose subcutaneous interleukin-2 plus β-interferon as a second-line therapy for metastatic colorectal carcinoma. Tumori, 79: 343-346, 1993.
39. Jiang, H., and Dhib-Jalbut, S. Differential induction of IL-12 by 1FN-β and IFN-γ in human macrophages. J. Interferon Cytokine Res., 18: 697-703, 1998.
40. Luft, T., Pang, K. C., Thomas, E., Hertzog, P., Hart, D. N., Trapani, J., and Cebon, J. Type I IFNs enhance the terminal differentiation of dendritic cells. J. Immunol., 161: 1947-1953, 1998.
41. Fleischmann, C. M., Stanton, G. J., and Fleischmann, W. R., Jr. Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages. J. Interferon Cytokine Res., 16: 805-812, 1996.
42. Sahasrabudhe, D. M., and Dusel, J. C. Effect of murine interferon α/β on tumour-induced suppressor function. Cancer Immunol. Immunother., 39: 360-366, 1994.
43. Marrack, P., Kappler, J., and Mitchell, T. Type 1 interferon keep activated T cell alive. J. Exp. Med., 189: 521-529, 1999.
44. Dong, Z., Yoneda, J., Kumar, R., and Fidler, I. J. Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/ macrophage colony- stimulating factor. J. Exp. Med., 183: 755-763, 1998.
45. Zhang, X., Alley, E. W., Russell, S. W., and Morrison, D. C. Necessity and sufficiency of β interferon for nitric oxide production in mouse peritoneal macrophages. Infect. Immunol., 62: 33-40, 1994.
46. Ortaldo, J. R., Mantovani, A., Hobbs, D., Rubinstein, M., Pestka, S., and Herberman, R. B. Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes. Int. J. Cancer, 31: 285-289, 1983.
47. Ortaldo, J. R., and Herberman, R. B. Augmentation of Natural Killer Activity: Immunobiology of Natural Killer Cells, Vol. II, pp. 145-154. Boca Raton, FL: CRC Press, 1986.
48. Oliveira, I. C., Sciavolino, P. J., Lee, T. H., and Vilcek, I. Downregulalion of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc. Natl. Acad. Sci. USA, 89: 9049-9053, 1992.
49. Gohji, K., Fidler, I. J., Tsan, R., Radinsky, R., von Eschenbach, A. C., Tsunio, T., and Nakajima, M. Human recombinant interferons-β and -γ decrease gelatinase production and invasion by human KG-2 renal carcinoma cells. Int. J. Cancer, 58: 380-384, 1994.
50. Fabra, A., Nakajima, M., Bucana, C. D., and Fidler, I. J. Modulation of the invasive phenotype of human colon carcinoma cells by organ specific fibroblasts of nude mice. Differentiation, 52: 101-110, 1992.
51. Donawho, C. K., and Kripke, M. L. Evidence that the local effect of ultraviolet radiation on the growth of murine melanoma is immunologically mediated. Cancer Res., 51: 4176-4181, 1991.
52. Fleischmann, C. M., Wu, T. Y., and Fleischmann, W. R., Jr. B16 melanoma cells exposed in vitro to long-term IFN-α treatment (B16 α cells) as activators of tumor immunity in mice. J. Interferon Cytokine Res., 17: 37-43, 1997.
53. Wu, T. Y., and Fleischmann, W. R., Jr. Efficacy of B16 melanoma cells exposed in vitro to long-term IFN-α treatment (B16 α cells) as a tumor vaccine in mice. J. Interferon Cytokine Res, 18: 829-839, 1998.
54. Horton, H. M., Anderson, D., Hemandez, P., Barnhart, K. M., Norman, J. A., and Parker, S. E. A gene therapy for cancer using intramuscular injection of plasmid DNA encoding interferon a. Proc. Natl. Acad. Sci. USA, 96: 1553-1558, 1999.